Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
75 hedge funds and large institutions have $217M invested in Generation Bio in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 25 increasing their positions, 26 reducing their positions, and 7 closing their positions.
41% more call options, than puts
Call options by funds: $24K | Put options by funds: $17K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.05% less ownership
Funds ownership: 8.72% → 8.68% (-0.05%)
4% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 26
5% less funds holding
Funds holding: 79 → 75 (-4)
31% less capital invested
Capital invested by funds: $315M → $217M (-$98.3M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.41M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$807K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$569K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$554K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$377K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$2.81M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$899K |
| 3 |
BlackRock
New York
|
-$868K |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$393K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$218K |
GBIO Hedge Fund Activity: Q3 2023 in Review
75 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q3 2023, worth a combined $217M — down 31% from $315M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GBIO and 3 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 25 added.
The largest buyer was JP Morgan Chase, adding an estimated $2.41M. The largest seller was Harvard Management Company, exiting entirely with an estimated $2.81M sold.
- 75 institutional investors held Generation Bio (GBIO) as of Q3 2023, down from 79 in Q2 2023.
- Funds reported $217M of Generation Bio stock for Q3 2023, down 31% quarter-over-quarter.
- 3 funds opened new Generation Bio positions in Q3 2023 and 7 closed out, a net change of -4 holders.
- The largest Generation Bio buyer in Q3 2023 was JP Morgan Chase, an estimated $2.41M added.
- The largest Generation Bio seller in Q3 2023 was Harvard Management Company, an estimated $2.81M sold.
Based on aggregated 13F filings for Q3 2023.